McKesson Stock Forecast, Price & News

-2.02 (-1.06 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.15 million shs
Average Volume1.05 million shs
Market Capitalization$29.96 billion
P/E RatioN/A
Dividend Yield0.88%
30 days | 90 days | 365 days | Advanced Chart
Receive MCK News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

McKesson logo

About McKesson

McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.09 out of 5 stars

Medical Sector

56th out of 2,100 stocks

Drugs, Proprietaries, & Sundries Industry

2nd out of 14 stocks

Analyst Opinion: 3.4Community Rank: 3.1Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

McKesson (NYSE:MCK) Frequently Asked Questions

Is McKesson a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" McKesson stock.
View analyst ratings for McKesson
or view top-rated stocks.

What stocks does MarketBeat like better than McKesson?

Wall Street analysts have given McKesson a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but McKesson wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting McKesson?

McKesson saw a drop in short interest during the month of May. As of May 28th, there was short interest totaling 1,560,000 shares, a drop of 18.8% from the May 13th total of 1,920,000 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is currently 1.5 days. Currently, 1.0% of the company's stock are sold short.
View McKesson's Short Interest

When is McKesson's next earnings date?

McKesson is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for McKesson

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) released its quarterly earnings results on Thursday, May, 6th. The company reported $5.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $5.02 by $0.03. The firm earned $59.10 billion during the quarter, compared to the consensus estimate of $61.08 billion. McKesson had a negative net margin of 1.91% and a positive trailing twelve-month return on equity of 95.80%. The company's revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the company earned $4.27 EPS.
View McKesson's earnings history

How has McKesson's stock price been impacted by Coronavirus (COVID-19)?

McKesson's stock was trading at $135.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MCK stock has increased by 40.1% and is now trading at $189.40.
View which stocks have been most impacted by COVID-19

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson declared a quarterly dividend on Thursday, April 29th. Investors of record on Tuesday, June 1st will be paid a dividend of $0.42 per share on Thursday, July 1st. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Monday, May 31st.
View McKesson's dividend history

Is McKesson a good dividend stock?

McKesson pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.88%. McKesson has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio of McKesson is 9.76%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, McKesson will have a dividend payout ratio of 8.30% next year. This indicates that McKesson will be able to sustain or increase its dividend.
View McKesson's dividend history.

How will McKesson's stock buyback program work?

McKesson announced that its board has authorized a share buyback plan on Tuesday, February 2nd 2021, which authorizes the company to repurchase $2,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 6.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's board of directors believes its shares are undervalued.

What guidance has McKesson issued on next quarter's earnings?

McKesson updated its FY 2022 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of 18.850-19.450 for the period, compared to the Thomson Reuters consensus EPS estimate of $18.850. The company issued revenue guidance of $245.38 billion-$252.52 billion, compared to the consensus revenue estimate of $250.66 billion.

What price target have analysts set for MCK?

10 brokerages have issued 12-month target prices for McKesson's shares. Their forecasts range from $166.00 to $257.00. On average, they expect McKesson's stock price to reach $214.00 in the next year. This suggests a possible upside of 13.0% from the stock's current price.
View analysts' price targets for McKesson
or view top-rated stocks among Wall Street analysts.

Who are McKesson's key executives?

McKesson's management team includes the following people:
  • Mr. Brian S. Tyler, CEO & Director (Age 54, Pay $5.56M) (LinkedIn Profile)
  • Mr. Britt J. Vitalone, Exec. VP & CFO (Age 52, Pay $2.3M) (LinkedIn Profile)
  • Ms. Lori A. Schechter, Exec. VP, Chief Legal Officer & Gen. Counsel (Age 59, Pay $2.71M) (LinkedIn Profile)
  • Ms. Tracy L. Faber, Exec. VP & Chief HR Officer (Age 51, Pay $1.26M) (LinkedIn Profile)
  • Mr. Sundeep G. Reddy, Sr. VP, Principal Accounting Officer & Corp. Controller (Age 47)
  • Ms. Nancy Flores, Exec. VP, Chief Information Officer & CTO (Age 54)
  • Ms. Holly Weiss, Sr. VP of Investor Relations
  • Mr. Pete Slone, Sr. VP of Corp. Public Affairs
  • Mr. Kirk Kaminsky, Pres of The US Pharmaceutical & Specialty Solutions Bus.
  • Paul A. Smith, Sr. VP of Taxes

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson CEO Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among McKesson's employees.

Who are some of McKesson's key competitors?

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include The Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and The Home Depot (HD).

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

Who are McKesson's major shareholders?

McKesson's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.03%), JPMorgan Chase & Co. (4.80%), Massachusetts Financial Services Co. MA (3.67%), Pzena Investment Management LLC (1.92%), Geode Capital Management LLC (1.81%) and Boston Partners (1.79%). Company insiders that own McKesson stock include Brian S Tyler, Britt J Vitalone, Lori A Schechter, M Christine Jacobs, Marie L/Ca Knowles, Sundeep G Reddy, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends for McKesson

Which institutional investors are selling McKesson stock?

MCK stock was sold by a variety of institutional investors in the last quarter, including Caisse DE Depot ET Placement DU Quebec, Millennium Management LLC, Dimensional Fund Advisors LP, Point72 Asset Management L.P., Great West Life Assurance Co. Can, Nuveen Asset Management LLC, Nordea Investment Management AB, and Northern Trust Corp. Company insiders that have sold McKesson company stock in the last year include Brian S Tyler, Britt J Vitalone, Lori A Schechter, Marie L/Ca Knowles, Sundeep G Reddy, Thomas L Rodgers, and Tracy Faber.
View insider buying and selling activity for McKesson
or view top insider-selling stocks.

Which institutional investors are buying McKesson stock?

MCK stock was bought by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Los Angeles Capital Management LLC, JPMorgan Chase & Co., BlackRock Inc., Glenview Capital Management LLC, Arrowstreet Capital Limited Partnership, Federated Hermes Inc., and Bank of New York Mellon Corp.
View insider buying and selling activity for McKesson
or or view top insider-buying stocks.

How do I buy shares of McKesson?

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $189.40.

How much money does McKesson make?

McKesson has a market capitalization of $29.96 billion and generates $238.23 billion in revenue each year. The company earns $-4,539,000,000.00 in net income (profit) each year or $17.21 on an earnings per share basis.

How many employees does McKesson have?

McKesson employs 76,000 workers across the globe.

Does McKesson have any subsidiaries?

The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, ClarusONE Sourcing Services LLP, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, MED3000, McKesson Europe AG, McKesson International Bermuda IP5A Limited, McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLC, McKesson Sourcing Services Inc., McKesson Specialty Care Distribution LLC, McKesson Strategic Services Limited, McKesson UK Finance I Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Northstar Healthcare Holdings Unlimited Company, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.

When was McKesson founded?

McKesson was founded in 1833.

What is McKesson's official website?

The official website for McKesson is www.mckesson.com.

Where are McKesson's headquarters?

McKesson is headquartered at 6555 STATE HWY 161, IRVING TX, 75039.

How can I contact McKesson?

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company can be reached via phone at 972-446-4800 or via email at [email protected]

This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.